Artificial intelligence continues to reshape biomedical research and diagnostics. Technologies such as deep learning models accurately predict microsatellite instability-high tumors, enhancing immunotherapy responsiveness predictions. AI tools have also been leveraged to design CRISPR protocols, enabling novice scientists to achieve high gene-editing efficiency. Furthermore, computational biology aids in engineering custom protein binders targeting cancer-specific molecules, and machine learning models predict organoid quality to accelerate regenerative medicine. These developments underscore AI's expanding role in accelerating drug discovery, precision diagnostics, and personalized treatment strategies.